Bisoprolol

Patient Information Leaflet

Warning! Keep this leaflet! Information on the outer packaging is in a foreign language.
Bisocard
5 mg, film-coated tablets
Bisoprolol fumarate
Please read this leaflet carefully before using the medicine, as it contains important information for the patient.

• Keep this leaflet so that you can read it again if necessary.
• If you have any doubts, please consult your doctor or pharmacist.
• This medicine has been prescribed for a specific individual. Do not pass it on to others. It may harm someone else, even if their symptoms are the same.
• If you experience any adverse effects, including any not listed in this leaflet, inform your doctor or pharmacist. See section 4.

Table of Contents

1. What Bisocard is and what it is used for
2. Important information before taking Bisocard
3. How to take Bisocard
4. Possible side effects
5. How to store Bisocard
6. Contents of the pack and other information

1. What Bisocard is and what it is used for

Bisocard is a medicine that selectively blocks beta-adrenergic receptors (present, among others, in the heart and blood vessels). It has beneficial effects, among others, in patients with heart failure and symptomatic stable systolic dysfunction, protecting the heart from excessive activity.

Bisocard is used in the treatment of:

• arterial hypertension;
• angina pectoris (chest pain due to inadequate oxygen supply to the heart);
• stable, moderate to severe chronic heart failure with impaired left ventricular systolic function (ejection fraction ≤ 35% as assessed by echocardiography), in combination with ACE inhibitors (angiotensin-converting enzyme inhibitors), diuretics, and, if necessary, digitalis glycosides.

2. Important information before using Bisocard

When not to use Bisocard:

• if the patient is allergic to bisoprolol fumarate or any of the other ingredients of this medicine (listed in section 6);
• if the patient has cardiogenic shock – a severe heart condition with rapid, weak pulse, low blood pressure, cold and clammy skin, weakness and fainting;
• if the patient has severe asthma or severe chronic obstructive pulmonary disease (COPD);
• if the patient has a slow heart rate (less than 60 beats per minute) – in case of doubt, consult a doctor;
• if the patient has very low blood pressure;
• if the patient has severe peripheral circulatory disorders (which may cause tingling, paleness or blueness of fingers and toes);
• if the patient has heart rhythm disorders – slow or irregular heartbeat;
• if the patient has developed acute heart failure or existing heart failure has worsened, requiring intravenous administration of drugs that increase the force of heart contractions;
• if the patient is concurrently using floctafenic acid (a non-steroidal anti-inflammatory drug) or sultopride (a medicine used to treat psychiatric disorders);
• if the patient has metabolic acidosis (a condition in which blood pH is too low);
• if the patient has an untreated phaeochromocytoma (a chromaffin tumour of the adrenal medulla).

Warnings and precautions
Before starting treatment with Bisocard, discuss the following with your doctor:

• if the patient has mild asthma or chronic obstructive pulmonary disease – bronchodilators should be used concomitantly, and their dose may need to be increased;
• if the patient has diabetes – Bisocard may mask symptoms of hypoglycaemia (low blood glucose levels);
• if the patient is on a strict diet;
• if the patient has first-degree atrioventricular block (a heart conduction disorder);
• if the patient has Prinzmetal's angina (chest pain caused by spasm of the coronary arteries supplying blood to the heart muscle);
• if the patient has mild peripheral circulatory disorders;
• if the patient has thyroid dysfunction (bisoprolol may mask some symptoms of hyperthyroidism, such as increased heart rate);
• if the patient has a chromaffin tumour (phaeochromocytoma) – prior to prescribing Bisocard, the doctor must initiate appropriate treatment;
• if the patient has (or has had in the past) psoriasis (a recurrent skin condition characterized by reddish-brown plaques and skin scaling);
• if the patient has ever experienced allergic reactions – Bisocard may increase sensitivity to allergens and intensify allergic reactions;
• if the patient is scheduled for allergen immunotherapy (treatment aimed at reducing allergy, e.g. to bee or wasp stings);
• if the patient is scheduled for surgery – Bisocard may alter the body's response to administered drugs.

Treatment of heart failure with Bisocard requires regular medical monitoring. This is essential, particularly at the beginning of treatment, during dose escalation, and when discontinuing therapy.
Consult your doctor if any of the above warnings apply to the patient or applied in the past.

Children and adolescents
Due to lack of experience with the use of bisoprolol in children and adolescents, its use is not recommended in this age group.

Bisocard with other medicines
Inform your doctor or pharmacist about all medicines currently used, recently used, or planned to be used.

The doctor will not recommend using Bisocard if the patient is taking the following medicines:

• floctafenic acid (a non-steroidal anti-inflammatory drug) or sultopride (a medicine used to treat psychiatric disorders).

Do not use the following medicines together with Bisocard without specific medical advice:

• certain medicines used to treat heart rhythm disorders (antiarrhythmics of class I, such as quinidine, disopyramide, lidocaine, phenytoin, flecainide, propafenone);
• certain medicines used to treat high blood pressure, angina pectoris, or heart rhythm disorders (calcium channel blockers such as verapamil and diltiazem);
• certain medicines used to treat high blood pressure, such as clonidine, methyldopa, moxonidine, rilmenidine. However, do not stop taking these medicines without consulting your doctor.

Before using the following medicines together with Bisocard, talk to your doctor – the doctor may recommend more frequent monitoring of the patient's condition:

• certain medicines used to treat high blood pressure or angina pectoris (dihydropyridine calcium channel blockers such as felodipine and amlodipine);
• certain medicines used to treat heart rhythm disorders (antiarrhythmics of class III, such as amiodarone);
• locally applied beta-blockers (e.g. eye drops containing timolol, used in glaucoma treatment);
• certain medicines used to treat, for example, Alzheimer's disease or glaucoma (parasympathomimetics such as donepezil or pilocarpine), or medicines used in acute heart disorders (sympathomimetics such as isoprenaline and dobutamine);
• antidiabetic medicines, including insulin;
• anaesthetics (e.g. during surgery);
• digitalis glycosides, used in the treatment of heart failure;
• non-steroidal anti-inflammatory drugs (NSAIDs), used to treat inflammatory conditions and relieve pain (e.g. ibuprofen and diclofenac);
• all medicines that may lower blood pressure, either as a desired or adverse effect, such as antihypertensives, certain tricyclic antidepressants (e.g. imipramine or amitriptyline), certain antiepileptics or drugs used during general anaesthesia (barbiturates, e.g. phenobarbital), and certain antipsychotics used in disorders involving loss of contact with reality (phenothiazine derivatives, e.g. levomepromazine);
• mefloquine, used for prevention and treatment of malaria;
• antidepressants known as monoamine oxidase inhibitors (MAOIs), such as moclobemide (except MAO-B inhibitors);
• rifampicin (an antibiotic);
• ergotamine derivatives (used to treat migraine).

Bisocard and alcohol
Alcohol may intensify dizziness and drowsiness caused by Bisocard. In such cases, alcohol consumption should be avoided.

Pregnancy and breastfeeding
There is a risk that using Bisocard during pregnancy may harm the unborn child.
If the patient is pregnant, breastfeeding, suspects she may be pregnant, or plans to become pregnant, she should consult a doctor or pharmacist before using this medicine. The doctor will decide whether Bisocard can be used during pregnancy.
It is not known whether bisoprolol passes into human milk; therefore, breastfeeding is not recommended during treatment with Bisocard.

Driving and operating machinery
Depending on the individual patient's response to treatment, the ability to drive or operate machinery may be impaired. This should be considered especially at the beginning of treatment, after dose increase, when changing medication, or when consuming alcohol.

Bisocard contains lactose monohydrate
If the patient has previously been diagnosed with intolerance to certain sugars, the patient should consult a doctor before taking this medicine.

Bisocard contains sodium
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means the medicine is considered "sodium-free".

3. How to use Bisocard

This medicine should always be used as directed by your doctor.
If you have any doubts, consult your doctor or pharmacist.
Bisocard is available in the following strengths: 5 mg, 10 mg.
The tablets should be taken in the morning. They may be taken with or without food. Swallow the tablets whole with liquid. Do not crush or chew them.
Bisocard should be taken once daily, at the same time each day.

Hypertension and angina pectoris
The dose is individually determined by the doctor for each patient, based on heart rate and treatment effectiveness.
The recommended starting dose is 5 mg once daily. If necessary, the dose may be increased to 10 mg once daily. Your doctor may decide to increase or decrease this dose.
The maximum recommended dose is 20 mg once daily.
In some milder cases of hypertension, a dose of 2.5 mg once daily may be sufficient.
Discontinuation of Bisocard or dose reduction should be done gradually, especially in patients with ischemic heart disease.

Renal or hepatic impairment
In patients with severe renal or hepatic impairment, the maximum dose is 10 mg per day.

Elderly patients
Dose adjustment is usually not necessary.

Heart failure (reduced cardiac contractility)
Your doctor will start treatment with a low dose of bisoprolol and gradually increase it—your doctor will decide how to adjust the dose. Typically, the dose escalation is as follows:

• 1.25 mg bisoprolol once daily for 1 week
• 2.5 mg bisoprolol once daily for 1 week
• 3.75 mg bisoprolol once daily for 1 week
• 5 mg bisoprolol once daily for 4 weeks
• 7.5 mg bisoprolol once daily for 4 weeks
• 10 mg bisoprolol once daily for maintenance (chronic) treatment

The maximum recommended daily dose is 10 mg bisoprolol.
Depending on how the medicine is tolerated, your doctor may recommend extending the interval before the next dose increase. If the condition worsens or if the medicine is not well tolerated, it may be necessary to reduce the dose again or discontinue treatment. In some patients, a maintenance dose lower than 10 mg bisoprolol may be sufficient.
Your doctor will determine the appropriate course of action.
If treatment needs to be interrupted, your doctor will usually recommend gradually reducing the dose; otherwise, the condition may worsen.

Hepatic or renal impairment
Your doctor will increase the dose particularly cautiously.

Elderly patients
Dose adjustment is usually not necessary.

Duration of treatment
Treatment with Bisocard is long-term. You should continue taking this medicine for as long as directed by your doctor.

Taking more Bisocard than recommended
If you take more than the prescribed dose, contact your doctor immediately or go to the nearest hospital emergency department. Bring any remaining tablets or this leaflet with you so that medical personnel know which medicine has been taken.
Symptoms of overdose may include dizziness, feeling faint, fatigue, shortness of breath, and/or wheezing. There may also be a slowed heart rate, hypotension, bronchospasm, acute heart failure, or seizures (caused by low blood glucose levels).

Missing a dose of Bisocard
Do not take a double dose to make up for a missed dose. If you forget to take your dose at the scheduled time, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose.

Stopping Bisocard
Do not stop taking Bisocard unless instructed by your doctor. Abruptly stopping this medicine may worsen the condition for which it was prescribed. Discontinuation of the medicine and dose reduction should be done gradually, especially in patients with ischemic heart disease.

If you have any further questions about the use of this medicine, consult your doctor or pharmacist.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone experiences them.
The adverse reactions listed below are classified according to their frequency of occurrence as follows:

Very common (may affect at least 1 in 10 people):

• slow heart rate (in patients with chronic heart failure).

Common (may affect less than 1 in 10 people):

• dizziness, headache;
• worsening of heart failure (in patients with chronic heart failure);
• sensation of coldness or numbness in the limbs (hands or feet);
• gastrointestinal disturbances such as nausea, vomiting, diarrhoea, constipation;
• very low blood pressure (hypotension), especially in patients with heart failure;
• feeling of fatigue, exhaustion (asthenia) in patients with chronic heart failure.

Uncommon (may affect less than 1 in 100 people):

• sleep disorders, depression;
• irregular heart rhythm or worsening of heart failure (in patients with hypertension or angina pectoris);
• slow heart rate (in patients with hypertension or angina pectoris);
• low blood pressure occurring upon changing position from lying or sitting to standing (postural hypotension);
• bronchospasm in patients with bronchial asthma or obstructive respiratory disease;
• muscle weakness and muscle cramps;
• asthenia in patients with hypertension or angina pectoris.

Rare (may affect less than 1 in 1,000 people):

• nightmares, hallucinations;
• fainting;
• dry eyes due to reduced tear production (which may be particularly bothersome in patients wearing contact lenses);
• hearing disturbances;
• allergic rhinitis;
• hepatitis;
• hypersensitivity reactions such as itching, sudden reddening of the skin, rash;
• reduced sexual function (impotence);
• increased levels of blood lipids (triglycerides) and increased liver enzyme activity (AlAT, AspAT).

Very rare (may affect less than 1 in 10,000 people):

• conjunctivitis;
• worsening of psoriasis symptoms or development of similar dry, scaly rash;
• hair loss.

Reporting of adverse reactions
If any adverse reactions occur, including any not listed in this leaflet, inform your doctor or pharmacist.
Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions at the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, telephone: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting adverse reactions helps provide more information on the safety of the medicine.

5. How to store Bisocard

Store below 30°C.
Keep in the original packaging to protect from light and moisture.
Store the medicine in a place out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the package and other information

What Bisocard contains

• The active substance is bisoprolol fumarate. One coated tablet contains 5 mg of bisoprolol fumarate.
• Other ingredients are: lactose monohydrate, maize starch, colloidal anhydrous silica, sodium lauryl sulfate, talc, magnesium stearate. Coating: hypromellose, macrogol 400, titanium dioxide (E 171), yellow iron oxide (E 172).

What Bisocard looks like and contents of the pack
Bisocard is a coated tablet.
Light yellow, round, biconvex tablets with a score line on one side and the mark “5” on the other.
This medicine is packed in PVC/Al blisters.
Pack sizes: 30, 60 or 120 coated tablets.
For more detailed information, please contact the responsible party or the parallel importer.
Marketing Authorisation Holder in the Czech Republic, country of export:
Bausch Health Ireland Limited
3013 Lake Drive, Citywest Business Campus
Dublin 24, D24PPT3
Ireland
Manufacturer:
ICN Polfa Rzeszów S.A.
Przemysłowa 2
35-959 Rzeszów
Poland
Parallel Importer:
InPharm Sp. z o.o.
Strumykowa 28/11
03-138 Warsaw
Repackaged by:
InPharm Sp. z o.o. Services sp. k.
Chełmżyńska 249
04-458 Warsaw
Marketing Authorisation Number in the Czech Republic, country of export: 77/300/02-C
Parallel Import Licence Number: 169/24